AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
At the May annual meeting of the American Psychiatric Association (APA) in Toronto, two reports supported vagus nerve stimulation (VNS) as a safe, long-term antidepressant treatment for treatment-resistant patients. Reuters reported (May 25) that Stephen K. Brannan, M.D., and colleagues at Cyberonics, Inc., makers of the VNS device, presented the results of a pilot study, which found that 72 percent of patients who …